AetherAI wins FDA, IVDR nods

Pathology is the lab specialty where doctors read tissue slides to decide whether a tumor is cancer, how far it has spread, and what to do next. aetherAI said April 28 its aetherSlide platform now has both U.S. Food and Drug Administration clearance and European CE marking for digital pathology use. (digitimes.com) (aetherai.com) A digital pathology system turns a glass slide into a very large image file that a pathologist can review on a screen instead of a microscope. aetherAI’s product page says aetherSlide is a web-based workflow system that manages whole-slide images and connects with AI tools for tasks like triage, lesion detection and immunohistochemistry quantification. (aetherai.com 1) (aetherai.com 2) In the United States, the key regulatory step is already on the record. The Food and Drug Administration database shows aetherSlide received 510(k) clearance K233126 on May 30, 2024, as a Class II device under the whole slide imaging system regulation. (fda.gov 1) (fda.gov 2) The FDA decision summary says the cleared indication covers viewing and managing digital images of scanned surgical pathology slides prepared from formalin-fixed, paraffin-embedded tissue for primary diagnosis. The same document says the software is not intended for frozen sections, cytology, or non-FFPE hematopathology specimens. (fda.gov) That matters because pathology images are huge, slow to move, and still often tied to scanner-specific workflows. The FDA summary says aetherSlide was cleared for use with the Philips Ultra Fast Scanner and Philips PS27QHDCR monitor, which sets the practical boundaries of the U.S. authorization. (fda.gov) Europe’s side of the story is less detailed in public databases, but aetherAI’s own product materials say aetherSlide is CE-marked, and Digitimes reported April 28 that the company is presenting the status as an IVDR credential as it expands overseas. (aetherai.com) (digitimes.com) aetherAI is using those approvals to sell a broader workflow, not just a slide viewer. Its product pages describe add-on applications for slide quality control, case triage, lymph-node metastasis detection in gastric cancer, and breast immunohistochemistry scoring for Ki67, ER and PR. (aetherai.com) The company has been building hospital references while it pushes abroad. aetherAI says aetherSlide was adopted in 2025 by RWTH Aachen University Hospital in Germany, several major medical centers in Taiwan, and Japan’s National Cancer Center Hospital East, Cancer Institute Hospital and Toyama Prefectural Central Hospital. (aetherai.com) aetherAI also says it raised NT$765 million in Series B funding in 2024 and filed for Taiwan’s Innovation Board in November 2025. Those details help explain why a Taiwan pathology software company is now emphasizing U.S. and European regulatory status at the same time. (aetherai.com) The immediate takeaway is narrower than the marketing pitch: aetherSlide has a documented U.S. clearance for primary diagnosis on certain scanned surgical pathology images, while aetherAI is using that and its European marking to pitch a global digital workflow for pathology labs. (fda.gov) (digitimes.com)